RA0077

antibody from Oursmab

Targeting: CD22 SIGLEC-2, SIGLEC2

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0077

Provider

Oursmab

Product name

Epratuzumab (Biosimilar Reference Antibody) (CD22)

Antibody type

Monoclonal

Description

Epratuzumab (development code hLL2) is a humanized monoclonal IgG1 antibody developed for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). It functions as a B-cell modulating therapy. Unlike B-cell depletion agents such as rituximab (anti-CD20), epratuzumab is considered a B-cell immunomodulator. It binds to a specific surface antigen on B cells, leading to the reduction of circulating B cells through mechanisms that appear to involve antibody-dependent cellular cytotoxicity (ADCC) and, more distinctly, the induction of tolerogenic signaling. This results in a more moderate, non-lytic modulation of B-cell activity and migration rather than profound depletion, aiming to dampen the abnormal autoimmune response without causing extensive immunosuppression.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.